Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response by Dimitriou, Florentia et al.








Sustainable responses in metastatic melanoma patients with and without
brain metastases after elective discontinuation of anti-PD1-based
immunotherapy due to complete response
Dimitriou, Florentia ; Zaremba, Anne ; Allayous, Clara ; Kähler, Katharina C ; Gerard, Camille L ;
Festino, Lucia ; Schäfer, Sarah ; Toussaint, Frédéric ; Heinzerling, Lucie ; Hassel, Jessica C ; Ascierto,
Paolo A ; Michielin, Olivier ; Hauschild, Axel ; Lebbe, Céleste ; Livingstone, Elisabeth ; Ramelyte, Egle
; Cheng, Phil F ; Dummer, Reinhard ; Mangana, Joanna
Abstract: BACKGROUND Anti-PD1-based immunotherapy is currently used in most patients with
advanced melanoma. Despite the remarkable data regarding overall survival, the optimal treatment
duration is still unknown. METHODS We evaluated the outcome of 125 patients with advanced melanoma
with and without brain metastases (MBM), treated either with anti-PD1 monotherapy (N = 97) or
combined with anti-CTLA4 (N = 28) after elective treatment discontinuation due to complete response
(CR) (group A, N = 86), or treatment-limiting toxicity (N = 33) and investigator’s decision (ID, N
= 6) (group B) with subsequent CR. RESULTS For group A, median duration of treatment (mDoT)
was 22 months (range 5-49) and median time to CR 9 months (range 2-47). Accordingly, mDoT for
group B was 3 months (range 0-36) and median time to CR 7 months (range 1-32). Seven patients from
group A and three from group B experienced disease recurrence. Off-treatment survival was not reached.
Median off-treatment response time (mOTRt) was 19 months (range 0-42) and 25 months (range 0-66),
respectively. For MBM, mOTRt was 17 months (range 7-41) and 28 months (range 9-39), respectively.
After a median follow-up of 38 months (range 9-70), seven (5.6%) patients had deceased, one (0.8%)
due to melanoma. CONCLUSIONS Treatment discontinuation is feasible also in patients with MBM.
Efficacy outcomes seemed to be similar in both groups of patients who achieved CR, regardless of reason
for discontinuation. In patients who experienced disease relapse, treatment re-challenge with anti-PD1
resulted in subsequent renewed response.
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Abstract Background: Anti-PD1ebased immunotherapy is currently used in most patients
with advanced melanoma. Despite the remarkable data regarding overall survival, the optimal
treatment duration is still unknown.
Methods: We evaluated the outcome of 125 patients with advanced melanoma with and
without brain metastases (MBM), treated either with anti-PD1 monotherapy (N Z 97) or
combined with anti-CTLA4 (NZ 28) after elective treatment discontinuation due to complete
response (CR) (group A, N Z 86), or treatment-limiting toxicity (N Z 33) and investigator’s
decision (ID, N Z 6) (group B) with subsequent CR.
Results: For group A, median duration of treatment (mDoT) was 22 months (range 5e49) and
median time to CR 9 months (range 2e47). Accordingly, mDoT for group B was 3 months
(range 0e36) and median time to CR 7 months (range 1e32). Seven patients from group A
and three from group B experienced disease recurrence. Off-treatment survival was not
reached. Median off-treatment response time (mOTRt) was 19 months (range 0e42) and 25
months (range 0e66), respectively. For MBM, mOTRt was 17 months (range 7e41) and 28
months (range 9e39), respectively. After a median follow-up of 38 months (range 9e70), seven
(5.6%) patients had deceased, one (0.8%) due to melanoma.
Conclusions: Treatment discontinuation is feasible also in patients with MBM. Efficacy out-
comes seemed to be similar in both groups of patients who achieved CR, regardless of reason
for discontinuation. In patients who experienced disease relapse, treatment re-challenge with
anti-PD1 resulted in subsequent renewed response.
ª 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
The application of antibody-mediated blockade of
cytotoxic T-lymphocyteeassociated antigen 4 (CTLA-4;
ipilimumab) and programmed cell-death protein 1 (PD-
1; pembrolizumab and nivolumab) immune checkpoint
inhibitors (ICIs) in the treatment of advanced melanoma
highly improved patient outcomes [1e4]. The durability
of responses and improved overall survival (OS) has led
to the widespread use of these immunotherapeutic
agents as first-line treatment in most patients regardless
of mutational status [1].
First evaluated in the KEYNOTE-001 study, pem-
brolizumab provided a response rate (RR) of 34% and
median OS of 25.9 months with sustainable responses
even after treatment discontinuation [5]. Combination
therapy with concurrent use of nivolumab and ipili-
mumab has shown even higher efficacy, with an RR of
57.6% [6]. Updated results from phase III clinical trials
show a sustained clinical benefit in both monotherapy
and combinational treatment, regardless of BRAF
mutational status [7,8]. It is also significant that 19% of
the patients treated with anti-PD1 monotherapy and
22% with ipilimumab/nivolumab achieve a complete
response (CR), which seems to be durable even after
treatment cessation. Notably, subgroup analysis from
randomized clinical trials indicate that progression-
free survival (PFS) rates in patients with CR who
discontinue pembrolizumab after at least 6 months are
similar to those who complete 2 years of treatment as
per the study protocol [4,9]. Despite these remarkable
data on OS, the optimal treatment duration is still
questionable.
In this retrospective multicenter study, we evaluated
the outcome of advanced melanoma patients treated
with anti-PD1ebased immunotherapy after discontinu-
ation of systemic therapy due to CR, or treatment-
limiting toxicity (TLT) and investigator’s decision (ID),
with subsequent CR.
2. Patients and methods
2.1. Patient selection and data acquisition
Fourteen expert centres were initially invited to partic-
ipate in this retrospective study, of which 8 centres from
4 European countries (Switzerland, Germany, Italy and
France) responded to the invitation. Clinical data of
advanced melanoma patients treated with anti-PD1 or
anti-PD1/anti-CTLA4 between January 2014 and
December 2019 were retrospectively reviewed from
institutional databases. Patients who discontinued
treatment either electively due to confirmed radio-
graphic or pathologic CR (group A) or due to a TLT or
ID (group B) with subsequent CR in both scenarios
included in the study. Patients with concurrent experi-
mental therapy (e.g. in terms of a clinical trial) and uveal
melanoma were excluded. Complete response (CR) was
defined as absence of radiographically apparent disease,
defined as inactive disease on FDG-PET/CT scan or as
fulfilling CR criteria as per RECIST v1.1. on CT/MRI
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scan (radiographic CR), and/or biopsy without evidence
of active disease in radiographically apparent residual
tissue (pathologic CR). Patients with complete meta-
bolic response on the FDG-PET/CT but with partial
response on CT/MRI scan were included. Reason for
treatment discontinuation was defined as the decision to
stop immunotherapy due to CR (elective discontinua-
tion) or in accordance with patient’s and investigator’s
decision, or due to a TLT. Patients were followed up for
at least 6 months from treatment discontinuation or
until disease progression or death or December 2019
(cutoff date of the analysis). Co-primary end-points
were off-treatment survival (OTS) and PFS, whereas OS
was the secondary end-point. A subgroup analysis
investigating the intracranial efficacy of these agents in
patients with melanoma brain metastasis (MBM) was
performed.
2.2. Statistical analysis
Descriptive statistics are presented as percentages of
total for categorical variables and as median for
continuous and ordinal variables. OS was defined as the
time (months) from treatment initiation to death, with
censoring on the last known alive date and was esti-
mated with the KaplaneMeier survival curves. OTS was
defined as the median time from last immunotherapy
dose to disease progression and PFS was calculated
from treatment initiation to disease progression. Off-
treatment response time (OTRt) was calculated as the
time between last immunotherapy dose to disease pro-
gression or last follow-up. A P-value of less than 0.05
was considered statistically significant. All analyses were
conducted using statistical language R version 3.5 (R
Foundation, USA).
2.3. Ethics statement
The analysis of the registry data was approved by the
local ethics committee (KEK-ZH 2014-0193).
3. Results
3.1. Patient characteristics
A total of 125 eligible patients with advanced melanoma
were identified. Anti-PD1 monotherapy (pem-
brolizumab or nivolumab) was administered in 77%
(N Z 97) of patients, whereas 22.4% (N Z 28) of the
patients were treated with combination anti-CTLA4/
anti-PD1 (ipilimumab/nivolumab or ipilimumab/pem-
brolizumab). Patients’ characteristics are summarized in
Table 1. Median follow-up (mFU) was 38 months
(range 9e70). Twenty-three patients (18.6%) were pre-
viously pretreated with adjuvant agents consisting
mostly of interferon-alpha (N Z 11) or ipilimumab
(N Z 1). In the non-resectable stage IV setting, anti-
Table 1
Patient’s and disease characteristics.
Characteristic Stop due to
CR
Stop due to TLT or
ID
N 86 39
Age at start of treatment (mean,
range)
65 (31e89) 70 (21e99)
Male gender (%) 51 (59.3) 31 (79.5)
Mutational status (%)
BRAF V600 mutant 30 (34.9) 16 (41)
NRAS mutant 19 (22.1) 7 (17.9)
BRAF wt 34 (39.5) 16 (41)
LDH elevated (%) 16 (18.6) 10 (25.6)
Melanoma type (%)
Cutaneous 72 (83.7) 28 (71.8)
Mucosal 1 (1.2) 1 (2.6)
Unknown primary 9 (10.5) 7 (17.9)
Ulceration (%) 26 (30.2) 12 (30.8)
Previous treatment lines
(metastatic setting, %)
0 36 (41.9) 31 (79.5)
1e2 45 (52.3) 6 (15.4)
3 5 (5.8) 2 (5.1)
Previous treatments
(metastatic setting, %)
One prior treatment line
Immunotherapy 18 (20.9) 1 (2.6)
Targeted therapy 9 (10.5) 0
Multiple prior treatment lines
Immunotherapy 11 (12.8) 1 (2.6)
Targeted therapy 2 (2.3) 2 (5.1)
Both 6 (7) 2 (5.1)
Disease stage, AJCC 8th (%)
III 7 (8.1) 7 (17.9)
IV 79 (92) 32 (82)
M stage (%)
M1a 16 (18.6) 2 (5.1)
M1b 26 (30.2) 6 (15.4)
M1c 23 (26.7) 13 (33.3)
M1d 14 (16.3) 11 (28.2)
Immunotherapy received (%)
Ipilimumab and nivolumab 6 (7) 19 (48.7)
Ipilimumab and pembrolizumab 2 (2.3) 1 (2.6)
Nivolumab 16 (18.6) 8 (20.5)
Pembrolizumab 62 (72) 11 (28.2)
Brain metastases (MBM) (%) 14 (16.3) 11 (28.2)
RECIST at 3 months after EOT (%)
CR 82 (95.3) 27 (69.2)
PR 0 10 (25.6)
SD 0 1 (2.8)
Unknown/NA 4 (4.7) 1 (2.8)
RECIST at 6 months after EOT (%)
CR 74 (86) 31 (86.1)
PD 1 (1.2) 0
PR 0 5 (13.9)
SD 0 1 (2.8)
Unknown/NA 11 (12.8) 2 (5.6)
RECIST at 12 months after EOT (%)
CR 56 (65.1) 26 (72.2)
PD 2 (2.3) 0
PR 0 2 (5.6)
SD 0 1 (2.8)
Unknown/NA 28 (32.6) 10 (27.8)
RECIST at > 12 months after EOT (%)
CR 48 (55.8) 24 (66.7)
PD 2 (2.3) 2 (5.6)
(continued on next page)
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PD1-based immunotherapy was administered as first-
line treatment in 67 (54%) patients. Excluding the cur-
rent anti-PD1-based treatment, patients were previously
treated with one (N Z 32, 26%) or two (N Z 19, 15%)
to a maximum of four (N Z 2, 1.6%) treatment lines
and pretreatment consisted mostly of ipilimumab
(N Z 37, 29.6%). At the time of anti-PD1 treatment
initiation, 111 (88.8%) patients had stage IV disease in
accordance with AJCC 8th edition. Involvement of two
or more organs was present in 68 (54%) patients and 25
(20%) patients had MBM. Serum lactate dehydrogenase
(LDH) was elevated in 26 (22%) patients of the study
population. Forty-six (38%) patients were BRAF
mutated.
3.2. Disease control and treatment discontinuation
Of the 125 patients who achieved CR, median duration
of treatment (mDoT) was 16 months (range 0e49) and
median time to CR was 8 months (range 1e47) since
start of immunotherapy (Fig. 1).
3.2.1. Treatment discontinuation due to CR (group A)
Eighty-six patients (68.8%) were considered histologi-
cally or radiologically CR and electively discontinued
the treatment in the absence of TLT (group A). Median
DoT was 22 months (range 5e49) and mDoT after the
1st documentation of CR was 8 months (range 0e40).
Median time to CR was 9 months (range 2e47).
3.2.2. Treatment discontinuation due to TLT or ID
(group B)
Thirty-nine (31.2%) patients electively discontinued the
treatment either due to TLT (N Z 33) or due to ID
(N Z 6), with subsequent CR (group B). Accordingly,
mDoT for this group was 3 months (range 0e36) and
median time to CR was 7 months (range 1e32). Most
patients who discontinued the treatment due to an im-
mune-related adverse event (irAE) had received
Table 1 (continued )
Characteristic Stop due to
CR
Stop due to TLT or
ID
Unknown/NA 36 (41.8) 13 (36.1)
Treatment outcome (months)
DoT (median, range) 22 (5e49) 3 (0e36)
Time to CR (median, range) 9 (2e47) 7 (1e32)
DoR (median, range) 28 (10e56) 24 (0e65)
OTRt (median, range) 19 (0e42) 25 (0e66)
CR, complete response; TLT, treatment-limiting toxicity; ID, in-
vestigators’ decision; DoT, Duration of Treatment, time from treat-
ment initiation to End of Treatment (EOT); Time to CR: time to
complete response, time from treatment initiation to first CR; DoR,
Duration of Response, time from documentation of tumour response
to disease progression; OTRt, off-treatment response time, time from
End of Treatment (EOT) until disease progression or death; PR,
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Fig. 1. Incidence of CR as per treatment time for the patient population. Median time to CR was 8 months (range: 1e47 months). CR,
complete response.
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combined immunotherapy (n Z 19 (57.6%)). Frequent
irAEs leading to treatment discontinuation (grade 3,
CTCAE v4) included gastrointestinal (N Z 8), endo-
crinological (N Z 6), pulmonary (N Z 5), hepatic
(N Z 4), cutaneous (N Z 3), musculoskeletal (N Z 2)
and neurological (N Z 2) toxicities.
3.3. Off-treatment survival, off-treatment response time,
subsequent treatment and disease outcome
In total, ten patients (8%) (N Z 7 group A and N Z 3
group B) ultimately experienced disease recurrence
(Figs. 2 and 3).
3.3.1. Treatment discontinuation due to CR (group A)
In group A, two patients who experienced disease
recurrence (1.6%) had been treated with combined anti-
CTLA4/anti-PD1 and five (4%) with anti-PD1 alone.
Subsequent treatments included re-challenge either with
anti-PD1 alone (N Z 3) or combined immunotherapy
(N Z 1), or locoregional salvage treatment consisting of
wide local excision (N Z 1) and radiotherapy (N Z 1).
One patient with previously known MBM had intra-
cranial PD with extracranial ongoing CR and was
treated with neurosurgery and anti-PD1 re-challenge. Of
the seven patients who relapsed, one patient (N Z 1)
developed de novo MBM and subsequently underwent
stereotactic radiotherapy (SRS) and anti-PD1 re-chal-
lenge. Six patients (4.8%) were progression free at data
cutoff after subsequent therapy, whereas one patient, in
whom no treatment was initiated after disease
recurrence, died due to melanoma progression. OTS was
not reached. The estimated median OTRt after treat-
ment discontinuation in this group was 19 months
(range 0e42) and DoR after declaration of CR was 28
months (range 10e56).
3.3.2. Treatment discontinuation due to TLT or ID
(group B)
Three (2.4%) patients, previously treated with combined
anti-CTLA4/anti-PD1 (N Z 1) and anti-PD1 alone
(NZ 2) experienced disease relapse in this patient group
(group B). Two of three patients had known MBM; one
patient (N Z 1) experienced intracranial relapse with
extracranial ongoing CR and was subsequently treated
with neurosurgery and anti-PD1 re-challenge, whereas
one patient (N Z 1) had extracranial recurrence with
intracranial ongoing CR and underwent wide local
excision, without systemic treatment. De novo MBM
was diagnosed in one patient (N Z 1) and was subse-
quently treated with SRS, without systemic treatment
initiation. All three patients were free-of progression at
data cutoff after the subsequent treatment, with esti-
mated median OTRt at 25 months (range 0e66) and
DoR at 24 months (0e65). OTS was not reached.
For group A and B, the estimated median OTRt was
21 months (range 0e66) and DoR after declaration of
CR was 37 months (range 9e70). Despite the numerical
difference between the two groups, no statistical signif-
icant difference in median OTRt was noted (28 and 24
months, respectively) (Table 1 and Fig. 4). In addition,
duration of CR was independent of the time to achieve
Study Population
N = 125
Stop due to CR
N = 86


























Ipi/Nivo N = 1
Surgery N =1
Pembro* N = 1
Pembro* + SRS N =1
None N = 1
* Treatment re – challenge
Radiotherapy N = 1
Pembro* + Neurosurgery N = 1
SRS N = 1
Pembro* + Neurosurgery N = 1
Surgery N = 1
CR: complete Response. TLT: Treatment limiting toxicity. ID: investigators` decision. SRS: stereotactic radiation
Fig. 2. Study population and disease recurrence characteristics as per reason of treatment discontinuation and the presence of MBM. Of
125 patients treated with anti-PD1ebased immunotherapy, ten patients (N Z 10) experienced disease recurrence. MBM, melanoma brain
metastases.
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CR in the different subgroups (Fig. 5). By December
31st, 2019, seven (5.6%) patients of the patient cohort
had deceased, although only one (0.8%) due to mela-
noma. Causes of death for the rest of the patients were
reported as advanced age (N Z 2), cardiac decompen-
sation (N Z 1), sepsis due to bacterial lung infection
(N Z 2) and unknown (N Z 1, other than disease
progression). Median OS was not reached, 3-year OS
was estimated at 90%.
3.3.3. Melanoma brain metastases
Twenty-five (20%) patients with MBM treated with anti-
PD1/anti-CTLA4 (N Z 9) or anti-PD1 alone (N Z 16)
were subsequently analysed as per DoR and OTRt.
MBM patients’ characteristics are summarized in Table
2. Apart from systemic treatment, 20 patients (80%)
required a local treatment either with SRS (N Z 16) or
with neurosurgery followed by SRS (N Z 4). At the
time of immunotherapy initiation, seven (28%) patients
were on steroids and nine (36%) patients had elevated
LDH. Eleven (44%) patients were BRAF mutated and
fifteen patients (60%) were treatment naı̈ve for the
metastatic setting. Intracranial response at first extra-
cranial CR was achieved in 19 (76%) patients, of which
15 (60%) patients had a CR, three (N Z 3) treated with
anti-PD1/anti-CTLA4, and twelve (N Z 12) with anti-
PD1 alone.
Fourteen (NZ14, 56%)patients electively discontinued
the systemic treatment due to extracranial and intracranial
CR and eleven (NZ 11, 44%) due to TLT (NZ 10) or ID
(NZ 1), with subsequent CR (Fig. 6). Median time to CR
was 12 months (range 2e30) for the CR group and 5
months (range 1e13) for the TLT/ID group.MedianDoR
was 29months (range 12e56) and 27months (range 7e42)
for the two groups, respectively. Median OTRt was
calculatedat 17months (range7e41) for theCRgroupand
28months (range 9e39) for the TLT/ID group (Fig. 4). At
the end of the observation period, twenty-two (88%) pa-
tients remained free of disease and three (N Z 3) patients
relapsed with extracranial (NZ 1) or intracranial (NZ 2)
relapse. Systemic treatment with anti-PD1ebased immu-
notherapy combined with neurosurgery was initiated in
Fig. 3. Swimmer plots showing the time to CR and durability of response from treatment start to the date of last observation or death, as
of December 2019, as per reason for treatment discontinuation. CR, complete response.
Fig. 4. KaplaneMeier probability curves for OTS and PFS from treatment discontinuation. PFS (A) and OTS (B) for the study popu-
lation. A separate analysis was performed for MBM, calculating the PFS (C) and OTS (D) probability, respectively. OTS, off-treatment
survival; PFS, progression-free survival; MBM, melanoma brain metastases.
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both patients with intracranial relapse, whereas extracra-
nial relapse was treated with wide local excision. All pa-
tients showed benefit form retreatment. As of December
2019, 23 patients were still alive and 2 had deceased due to
reduced performance status, without evidence of PD.
4. Discussion
In this multicenter study of patients with advanced
melanoma who electively discontinued anti-PD1ebased
immunotherapy due to CR, we observed sustained re-
sponses, suggesting that treatment discontinuation is
feasible also in patients with MBM. Although the
discontinuation criteria were not homogeneous for the
treatment population, the probability of being alive
without additional therapy at 3 years was 92%. In pa-
tients who experienced disease relapse after treatment
discontinuation, re-challenge with anti-PD1ebased ICI
was mostly preferred from the investigators with
renewed response. Likewise, durable responses after
early treatment cessation were reported in patients with
melanoma who had achieved CR in the KEYNOTE-001
study, with 91% remaining free of disease after a mini-
mum of 5 years follow-up [8]. Re-treatment with anti-
PD1 could be effective, as similarly reported in the
KEYNOTE-006 study [4] and in a recent, retrospective
analysis [10].
Notably, sustained disease control was observed in
115 patients who discontinued the systemic treatment
due to TLT or ID. Compared with the patients with
treatment discontinuation due to CR, mDoT in this
patient group was significantly shorter (3 months and 22
months, respectively), indicating that most patients who
discontinued due to an irAE did so early after the ICI
initiation. Still, median time to CR (7 and 8 months,
respectively), as well as efficacy outcomes seemed to be
similar in both groups with no difference in median
OTRt. These data are in line with previously reports
investigating the safety and efficacy in patients treated
with ipilimumab and nivolumab who discontinued due
to an irAE [11], suggesting that irAEs provide evidence
that an immune reaction has been activated. Whether
this activation correlates with an increased antitumour
activity and thus, favourable prognosis remains unclear
[12].
Patients with MBM have a dismal prognosis and
until recently they were typically excluded from clinical
trials. Two randomized, phase 2 clinical trials showed
that anti-PD1ebased ICIs and especially combined
immunotherapy with ipilimumab/nivolumab are intra-
cranially active [13,14]. In our pooled population, 20%
of the patients had active MBM during the treatment
initiation and at the time of treatment discontinuation,
the vast majority of the patients had concordant extra-
cranial and intracranial efficacy. Still, 84% of the
| | || | || | || | | | | | | | |||| | | || || ||| | | || | | | | |
| | | | | | | ||||| | |||| | | | | | | | | || || | |
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| |
|






0 12 24 36 48 60

















>=6m and <12m n=39
>=12m and <18m n=22
>=18m n=20
Time to progression after CR
44 41 29 17 4 1
39 36 28 11 2 0
22 20 8 2 0 0
20 17 9 3 1 0−−
−−
0 12 24 36 48 60








Fig. 5. KaplaneMeier probability curves for time to progression after achieving CR, compared with the time to CR for <6 months,  6
months and <12 months, 12 months and <18 months and 18 months. CR, complete response.
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patients received a local treatment, consisting mostly of
SRS, suggesting that in real-life, local management is
still preferred from investigators, regardless of concur-
rent systemic treatment initiation and the possible
increased risk of radionecrosis [15]. Median time to CR
was according to patients without MBM, regardless of
reason for treatment cessation. Similarly, although
mDoT differed between group A and B patients, median
OTRt was similar. In patients who progressed, no pat-
terns of progression could be identified, but not all pa-
tients who progressed had an intracranial progression.
However, the numbers are too small to draw any
conclusions.
Despite a principal approval for a long-term use, the
optimal treatment duration of ICI is still a matter of
debate. In clinical trials, anti-PD1 antibodies are
typically administered continuously over 2 years, or
until reaching a TLT or PD. In the KEYNOTE-001
study treatment cessation was allowed for patients
achieving CR and 6 months of treatment and at least 2
treatments after CR confirmation [8]. In our study,
mDoT for the patients who electively discontinued due
to CR was 22 months and mDoT after CR 8 months.
Recent data identified a significantly increased risk of
subsequent relapse in patients treated with anti-PD-1
treatment for <6 months versus >6 months [10].
Although previous reports indicate that prolonged
treatment does not result in an increased incidence of
AEs [16], the incidence of long-term toxicities is still
unknown [17]. To date, there are still no definite pre-
dictors for treatment response and indicators for cessa-
tion decisions. Recent post hoc results from the
KEYNOTE-001 clinical trial have provided evidence
that tumour size and PD-L1 status at the baseline were
associated with CR by univariate analysis [9]. Despite
recent findings supporting that metabolic CR on FDG-
PET scans is likely to influence the treatment duration
decision [18], two retrospective studies of real-life pa-
tients achieving CR and discontinuing treatment in
absence of TLT reported that a significant number of
patients showed persisting radiological evidence of dis-
ease [10,19]. Previously published studies have linked
lower frequency of BRAF V600 mutation and elevated
LDH, as well as lower tumour stage and incidence of
MBM with better clinical outcome [10].
The retrospective nature of the data, the patients’
selection (only complete responders) and the lack of an
established consensus for treatment discontinuation,
as well as the lack of central radiologic review are
possible limitations of this analysis. In real life, sig-
nificant amount of ICI-treated patients achieve a PR
as best overall response, in accordance with the
RECIST 1.1 criteria. In this study, patients with PR on
the CT/MRI scan but CR on the FDG-PET/CT were
included. ICI cessation of partial responders either
electively or due to TLT with subsequent PR was not
the focus of the present study. However, it remains one
of the major challenges for physicians, as they are
often confronted by a patient’s will to continue ICI
despite notable toxicity in some cases, remarkable
treatment-related costs and the fact that risk of sub-
sequent relapses is higher in patients achieving PR
than in those with CR.
Although treatment discontinuation after achieving
CR seems feasible, the discontinuation criteria for
stopping treatment merit additional investigation.
Despite the relatively small number of re-treatments
after disease relapse, our cohort indicates that re-
treatment is feasible and may lead to renewed anti-
tumour activity in patients after treatment discontin-
uation. Randomized, prospective studies are recom-
mended to evaluate an optimal and pragmatic
treatment duration to prevent over- and under-
Table 2






Male gender (%) 10 (71.4)) 9 (81.8)
Age at start of treatment (mean, range) 66 (31e89) 73 (39e82)
Mutational status (%)
BRAF V600 mutant 3 (21.4) 8 (72.7)
NRAS mutant 6 (42.9) 0
BRAF wt 5 (35.7) 3 (27.3)
Elevated baseline LDH 3 (21.4) 6 (54.5)
Previous treatment lines
(metastatic setting, %)
0 7 (50) 8 (72.7)
1e2 6 (42.9) 1 (18.2)
 3 1 (7.1) 2 (18.2)
Immunotherapy received (%)
Ipilimumab and nivolumab 2 (14.3) 6 (54.5)
Ipilimumab and pembrolizumab 1 (7.1) 0
Nivolumab 0 2 (18.2)
Pembrolizumab 11 (78.6) 3 (27.3)
Treatment of MBM (%)
SRS 8 (57.1) 8 (72.7)
SRS þ OP 4 (28.6) 0
None 2 (14.3) 3 (27.3)
Steroids needed (%)
Yes 4 (28.6) 3 (27.3)
Intracranial response at EOT (%)
CR 11 (78.6) 4 (36.4)
PR 0 4 (36.4)
SD 3 (21.4) 2 (18.2)
Treatment outcome (months)
DoT (median, range) 23 (11e49) 2 (0e31)
Time to CR (median, range) 12 (2e30) 5 (1e13)
DoR (median, range) 29 (12e56) 27 (7e42)
OTRtS (median, range) 17 (7e41) 28 (9e39)
CR, complete response; TLT, treatment-limiting toxicity; ID, in-
vestigators’ decision; DoT, Duration of Treatment, time from treat-
ment initiation to End of Treatment (EOT); Time to CR, time to
complete response, time from treatment initiation to first CR; DoR,
Duration of Response, time from documentation of tumour response
to disease progression; OTRt, off-treatment response time, time from
End of Treatment (EOT) until disease progression or death; PR,
partial response; SD, stable disease; SRS, stereotactic radiation; OP,
operation (neurosurgery).
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treatment, long-term toxicities and financial costs
from overtreatment.
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Fig. 6. Swimmer plots showing the treatment course for patients with MBM. Time to CR and durability of response from treatment start
to the date of last observation or death, according to reason for treatment discontinuation. Data cutoff in December 2019. MBM,
melanoma brain metastases; CR, complete response.
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